Tercica’s False Advertising Suit Against Insmed Is Dismissed In California
This article was originally published in The Pink Sheet Daily
Executive Summary
San Francisco federal court finds that Insmed's statements to investors about the safety profile of Tercica's growth hormone Increlex do not constitute false advertising.